Table 1.
Patient characteristics.
| IBD total N = 92 | CD N = 49 | UC N = 43 | HC N = 20 | ||||
|---|---|---|---|---|---|---|---|
| Remission | Active | Remission | Active | Remisson | Active | ||
| N [%] | 50 | 42 | 26 | 23 | 24 | 19 | 20 |
| Age [years], mean ± SEM | 44.78 ± 1.7 | 49.4 ± 2.4 | 44.15 ± 2.5 | 47.65 ± 3.1 | 45.46 ± 2.2 | 51.53 ± 3.8 | 44.25 ± 2.9 |
| IBD activity score, median/25th percentile/75th percentile | - | - | 2/0/3 | 6/5/9 | 1/0/2 | 5/4/6 | - |
| C-reactive protein [mg/L], mean ± SEM | 4.9 ± 1.0 | 9.5 ± 1.7 | 5.3 ± 1.5 | 13.1 ± 2.8 | 3.4 ± 1.2 | 5.2 ± 0.9 | 1.2 ± 0.2 |
| BMI [kg/m2], mean ± SEM | 24.9 ± 0.5 | 25.6 ± 0.7 | 24.5 ± 0.7 | 25.2 ± 1.0 | 25.4 ± 0.6 | 26.0 ± 1.0 | 25.3 ± 0.6 |
| Smoking, N | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Known EIM of IBD, N [%] | 5 [10] | 13 [31] | 5 [19] | 5 [22] | 0 [0] | 8 [42] | - |
| Concomitant medication, N [%] | |||||||
| 5-ASA | 19 [38] | 14 [33] | 2 [8] | 2 [9] | 14 [58] | 12 [63] | - |
| Steroids | 8 [16] | 14 [33] | 6 [23] | 6 [26] | 2 [8] | 8 [42] | - |
| Budesonide | 7 [14] | 3 [7] | 1 [4] | 3 [13] | 6 [25] | 0 [0] | - |
| Azathioprine | 2 [4] | 6 [14] | 1 [4] | 2 [9] | 1 [4] | 4 [21] | - |
| Anti-TNF-α | 21 [42] | 0 [0] | 11 [42] | 0 [0] | 10 [42] | 0 [0] | - |
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; HC, healthy controls; SEM, standard error of the mean; BMI, body mass index; EIM, extraintestinal manifestations; 5-ASA, 5-aminosalicylic acid; TNF, tumour necrosis factor.